網膜静脈閉塞症治療市場：治療タイプ、年齢層、疾患タイプ、エンドユーザー別-2025-2030年の世界予測

網膜静脈閉塞症治療市場は、2024年には29億1,000万米ドルとなり、2025年にはCAGR 6.44%で30億9,000万米ドルに成長し、2030年には42億3,000万米ドルに達すると予測されています。

網膜静脈閉塞症治療市場は、医療画像の進歩や急速に台頭してきた治療法に牽引され、大きな進化を遂げてきました。過去数年間で、網膜血管障害の対処法を再構築する画期的な研究・臨床データへの道が開かれました。本分析では、現在の市場力学と新たな動向、成長機会を包括的に概観します。治療選択肢の歴史的背景をナビゲートし、新たな治療介入が患者の転帰に与える影響を解説します。市場の根深い課題は現在、科学の進歩と臨床の実用性をシームレスに組み合わせた革新的なソリューションによって解決されつつあります。今日、患者管理は個別化されたアプローチによってますます特徴付けられ、技術の進歩は多様な患者集団における投与技術を洗練させる上で極めて重要な役割を果たしています。さらに、臨床プロトコールと治療レジメの進化が、全体的な状況を強化しています。このエグゼクティブサマリーは、業界の現状を明確かつ簡潔にまとめ、臨床上の意思決定や投資の見通しを形成し続ける、進化する期待、競合からのプレッシャー、規制の変更に言及することを目的としています。

網膜静脈閉塞症治療市場の変革

近年、網膜静脈閉塞症治療の状況は大きく変化しており、治療法における画期的な進歩が臨床を再定義しています。洗練された注射技術から適応性の高いコルチコステロイド製剤の開発まで、治療技術の絶え間ない進歩により、網膜障害の根本的な原因を標的とした精度の向上が促進されています。これと並行して、レーザー治療と革新的な薬理学的薬剤を統合した併用アプローチの有効性が臨床試験で検証されるようになり、治療の安全性と有効性の両方が向上しています。また、規制機関も新たな治療法の承認に向けた明確な道筋を示し始めたため、利害関係者の信頼が高まり、研究資金の流入につながっています。このような変化は、研究室で得られた知見をより効率的に臨床に反映させるだけでなく、医療機器メーカー、製薬会社、開業医の間の協力関係も促進しています。治療手法の急速な進化は、診断の明確化と患者固有の治療計画が最重要である個別化医療に業界全体が焦点を当てていることを反映しています。このような変革的なシフトを取り入れることで、市場のプレーヤーは、高齢化が進み、健康志向が高まる患者層のニーズを満たすために絶えず進化するダイナミックな空間の最前線に自らを位置づけています。

こうした進化する戦略は、ケアにおけるギャップに対処し、長期的な患者の転帰を改善するという業界のコミットメントを強調するものです。スピード、革新性、規制の進歩が融合し、既存企業にも新規参入企業にもかつてないビジネスチャンスが生み出されています。

主要セグメントに関する洞察

市場のセグメンテーションを詳細に調査した結果、網膜静脈閉塞症治療の範囲と規模を理解する上で欠かせないいくつかの重要な側面が明らかになりました。最初の次元は治療タイプで、抗VEGF注射、コルチコステロイド治療、レーザー治療の各モダリティで市場を調査しています。抗VEGF注射のカテゴリーでは、治療法はさらにアフリベルセプト、ベバシズマブ、ラニビズマブといった特定の薬剤に分類され、それぞれが有効性と市場浸透度において独自のプロファイルを示しています。もう一つの側面として、年齢層別セグメンテーションは、40～60歳、60歳以上、40歳未満の分析から重要な洞察が得られるなど、さまざまな層における治療に関する考察を明らかにします。この分類は網膜静脈分枝閉塞症と網膜中心静脈閉塞症を明確に分け、臨床像と治療成績の違いを浮き彫りにします。最後に、エンドユーザーセグメンテーションのレンズを通して市場力学を理解することで、外来手術センター、病院、専門クリニックが果たすさまざまな役割が明確になります。これらのセグメンテーションの洞察は、患者集団の異質性とともに、利用可能な治療アプローチを強調するものであり、利害関係者が介入策をより適切に調整し、リソースを効果的に配分できるようにするものです。全体として、セグメンテーション分析は市場動向の予測精度を高めるだけでなく、進化するヘルスケア情勢の中で戦略を策定するための重要なツールとしても機能します。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 糖尿病や高血圧などのリスク要因の増加により、効果的な治療法が必要となっている
    • ヘルスケア費の増加により網膜静脈閉塞症治療オプションへの投資が促進される
  • 抑制要因
    • 網膜静脈閉塞症治療に関連するコストが高く、払い戻しポリシーが限られている
  • 機会
    • 網膜静脈閉塞症の長期管理のための遺伝子治療技術の継続的な進歩
    • 網膜静脈閉塞症の早期発見と個別治療計画における人工知能の導入
  • 課題
    • 網膜静脈閉塞症治療の患者管理における合併症
• 市場セグメンテーション分析
  • 治療の種類：黄斑浮腫の管理に抗VEGF注射が広く採用されている
  • 病状タイプ：網膜静脈分枝閉塞症の罹患率増加により高度な治療の需要が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 網膜静脈閉塞症治療市場治療の種類別

• 抗VEGF注射
  • アフリベルセプト
  • ベバシズマブ
  • ラニビズマブ
• コルチコステロイド治療
• レーザー治療

第7章 網膜静脈閉塞症治療市場：年齢層別

• 40-60
• 60歳以上
• 40歳未満

第8章 網膜静脈閉塞症治療市場症状タイプ別

• 網膜静脈分枝閉塞症
• 網膜中心静脈閉塞症

第9章 網膜静脈閉塞症治療市場：エンドユーザー別

• 外来手術センター（ASC）
• 病院
• 専門クリニック

第10章 南北アメリカの網膜静脈閉塞症治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の網膜静脈閉塞症治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの網膜静脈閉塞症治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie
• Alimera Sciences, Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• Carl Zeiss AG
• Fovea Pharmaceuticals SA
• Genentech, Inc.
• GlaxoSmithKline plc
• IRIDEX Corporation
• Johnson & Johnson Services, Inc.
• Lumenis Ltd.
• Novartis AG
• Pfizer Inc.
• Ranbaxy Pharmaceuticals Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi S.A.
• Suzuken Co., Ltd.
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. RETINAL VEIN OCCLUSION TREATMENT MARKET MULTI-CURRENCY
• FIGURE 2. RETINAL VEIN OCCLUSION TREATMENT MARKET MULTI-LANGUAGE
• FIGURE 3. RETINAL VEIN OCCLUSION TREATMENT MARKET RESEARCH PROCESS
• FIGURE 4. RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 17. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 19. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. RETINAL VEIN OCCLUSION TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 25. RETINAL VEIN OCCLUSION TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. RETINAL VEIN OCCLUSION TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. RETINAL VEIN OCCLUSION TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CORTICOSTEROID TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY 40-60, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ABOVE 60, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY BELOW 40, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS (ASCS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. CANADA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 43. CANADA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 44. CANADA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 45. CANADA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CANADA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. CHINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 70. CHINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 71. CHINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 72. CHINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 73. CHINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. INDIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 75. INDIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 76. INDIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 77. INDIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 78. INDIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 160. ITALY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 161. ITALY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 162. ITALY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 163. ITALY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 164. ITALY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 180. POLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 181. POLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 182. POLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 183. POLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 184. POLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 185. QATAR RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 186. QATAR RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 187. QATAR RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 188. QATAR RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 189. QATAR RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 235. RETINAL VEIN OCCLUSION TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 236. RETINAL VEIN OCCLUSION TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

The Retinal Vein Occlusion Treatment Market was valued at USD 2.91 billion in 2024 and is projected to grow to USD 3.09 billion in 2025, with a CAGR of 6.44%, reaching USD 4.23 billion by 2030.

The retinal vein occlusion treatment market has experienced significant evolution, driven by advances in medical imagery and rapidly emerging therapeutic modalities. In the past few years, research and clinical data have paved the way for breakthroughs that are reshaping how retinal vascular disorders are addressed. This analysis provides a comprehensive overview of current market dynamics along with emerging trends and opportunities for growth. The discussion navigates through the historical context of treatment options and explains the impact of novel therapeutic interventions on patient outcomes. The market's deep-rooted challenges are now being met with innovative solutions that seamlessly combine scientific advancement with clinical practicality. Today, patient management is increasingly characterized by a personalized approach, and technological advancements have played a pivotal role in refining administration techniques across diverse patient populations. Moreover, the evolution of clinical protocols and therapeutic regimes has bolstered the overall landscape. This executive summary aims to offer a clear and concise synthesis of the industry's status while addressing evolving expectations, competitive pressures, and regulatory changes that continue to shape clinical decisions and investment prospects.

Transformative Shifts in the Landscape

Recent years have witnessed transformative shifts within the retinal vein occlusion treatment landscape, as breakthroughs in therapeutic modalities now redefine clinical practices. Continuous advancements in treatment technologies-ranging from refined injection techniques to the development of adaptive corticosteroid formulations-facilitate enhanced precision in targeting the underlying causes of retinal damage. In parallel, clinical trials are increasingly validating the effectiveness of combination approaches that integrate laser therapy with innovative pharmacological agents, thereby improving both the safety and efficacy profiles of treatments. Regulatory bodies have also begun to provide clearer pathways for the approval of emerging therapies, which has bolstered confidence among stakeholders and led to an influx of research funding. These changes are not only facilitating a more efficient translation of laboratory findings into clinical solutions but are also encouraging collaborations among medical device manufacturers, pharmaceutical companies, and practitioners. The swift evolution in treatment methodologies reflects an industry-wide focus on personalized medicine, where diagnostic clarity and patient-specific treatment plans are paramount. By embracing these transformative shifts, market players are positioning themselves at the forefront of a dynamic space that continuously evolves to meet the needs of an aging and increasingly health-conscious patient demographic.

These evolving strategies underscore the commitment of the industry to address gaps in care and improve long-term patient outcomes. It is a landscape where speed, innovation, and regulated progress converge to create unprecedented opportunities for both incumbents and newer entrants.

Key Segmentation Insights

An in-depth study of the market's segmentation reveals several critical dimensions that are vital for understanding the scope and scale of retinal vein occlusion treatment. The first dimension examines treatment type, where the market is studied across anti-VEGF injection, corticosteroid treatment, and laser therapy modalities. Within the anti-VEGF injection category, therapies are further delineated into specific drugs such as Aflibercept, Bevacizumab, and Ranibizumab, each presenting its own distinct profile in terms of efficacy and market penetration. In another dimension, age group segmentation sheds light on treatment considerations across varying demographics, with key insights emerging from analysis among individuals aged between 40-60, those above 60, and even those below 40. Thirdly, the segmentation based on condition types is crucial; the classification distinctly separates branch retinal vein occlusion from central retinal vein occlusion, highlighting differences in clinical presentation and treatment outcomes. Lastly, understanding market dynamics through the lens of end user segmentation provides clarity regarding the varied roles played by ambulatory surgical centers, hospitals, and specialty clinics. These segmentation insights collectively emphasize the heterogeneity of the patient population as well as the therapeutic approaches available, situating stakeholders to better tailor interventions and allocate resources effectively. Overall, the segmentation analysis not only enhances predictive accuracy for market trends but also serves as a critical tool for strategy formulation within this evolving healthcare landscape.

Based on Treatment Type, market is studied across Anti-VEGF Injection, Corticosteroid Treatment, and Laser Therapy. The Anti-VEGF Injection is further studied across Aflibercept, Bevacizumab, and Ranibizumab.

Based on Age Group, market is studied across 40-60, Above 60, and Below 40.

Based on Condition Type, market is studied across Branch Retinal Vein Occlusion and Central Retinal Vein Occlusion.

Based on End User, market is studied across Ambulatory Surgical Centers (ASCs), Hospitals, and Specialty Clinics.

Key Regional Insights

A regional analysis uncovers significant variances in market dynamics across key geographies. Insights drawn from the Americas reveal thriving ecosystems bolstered by robust healthcare systems and sustained investments in ophthalmological research, positioning the area as a leader in clinical innovations. In regions spanning Europe, the Middle East, and Africa, regulatory frameworks and collaborative initiatives among public and private sectors drive consistent progress in treatment uptake and research. Meanwhile, the Asia-Pacific region is characterized by accelerating advancements in technology and a rapidly expanding patient base, which in turn fuels higher demand for affordable and effective treatment options. Across these regions, trends in healthcare expenditure and patient-centric innovations have laid the groundwork for exponential growth in clinical services, while demographic shifts and an increasing prevalence of chronic conditions further underscore the significance of these findings. The analysis highlights that each geographical zone brings unique perspectives and challenges, yet all are aligned around the central goal of improving clinical outcomes through state-of-the-art therapeutic interventions.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

An examination of the competitive landscape identifies a cohort of prominent companies that are at the forefront of advancing retinal vein occlusion treatments. Leading innovators such as AbbVie, Alimera Sciences, Inc., Bayer AG, and Bristol-Myers Squibb Company have been actively engaged in research-driven advancements that shape market strategies and therapeutic outcomes. These industry players are complemented by other significant contributors including Carl Zeiss AG, Fovea Pharmaceuticals SA, Genentech, Inc., and GlaxoSmithKline plc, each bringing specialized expertise that reinforces market progress. Companies like IRIDEX Corporation and Johnson & Johnson Services, Inc. have leveraged technological advancements to streamline treatment protocols, while Lumenis Ltd. and Novartis AG continue to drive innovation through precision-based methodologies. Further, the contributions of Pfizer Inc., Ranbaxy Pharmaceuticals Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Suzuken Co., Ltd., and Teva Pharmaceutical Industries Ltd. ensure a competitive balance. Their continued focus on product quality, clinical safety, and global outreach creates a landscape that is dynamic, competitive, and ripe for new innovations. This collective focus on research, strategic partnerships, and robust product pipelines is central to understanding the current market structure and anticipating future developments in treatment modalities.

The report delves into recent significant developments in the Retinal Vein Occlusion Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Alimera Sciences, Inc., Bayer AG, Bristol-Myers Squibb Company, Carl Zeiss AG, Fovea Pharmaceuticals SA, Genentech, Inc., GlaxoSmithKline plc, IRIDEX Corporation, Johnson & Johnson Services, Inc., Lumenis Ltd., Novartis AG, Pfizer Inc., Ranbaxy Pharmaceuticals Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Suzuken Co., Ltd., and Teva Pharmaceutical Industries Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders must adopt agile and forward-thinking strategies that address both current challenges and future opportunities in retinal vein occlusion treatment. Emphasis should be placed on investing in innovation and integrating advanced therapeutic techniques, particularly in the realm of anti-VEGF injections and laser therapy enhancements, while remaining vigilant about the evolving competitive landscape. Leaders are encouraged to foster collaborations across research institutions and clinical networks to leverage emerging data for more effective patient outcomes. A strategic focus on tailoring treatment approaches to distinct patient segments, with an acute understanding of age-based nuances and specific condition types, lies at the heart of optimizing clinical efficacy. Furthermore, prioritizing investments in technology infrastructure is crucial to sustain competitive advantage in a market that rapidly evolves due to digital and data-driven healthcare innovations. Comprehensive commercial strategies should also incorporate risk assessment, regulatory compliance, and marketing initiatives that resonate with diverse end users including hospitals, ambulatory centers, and specialty clinics. Proactive engagement with key opinion leaders and incorporation of real-world evidence into decision-making processes can further enhance market positioning. Ultimately, a balance between clinical excellence and business agility is essential for preserving market leadership while adapting to emerging clinical trends and patient demands.

Conclusion: Strategic Considerations for the Future

The evolution of retinal vein occlusion treatment underscores a fundamental shift toward precision, patient-centric approaches, and innovation-driven growth. Advancements in therapeutic modalities, coupled with a nuanced understanding of market segmentation and regional trends, are defining the framework of this dynamic market. Key insights into treatment types, patient demographics, clinical conditions, and operational channels not only enhance the strategic positioning of industry players but also foster a competitive environment that incentivizes continuous improvement. As we look to the future, embracing technological progress and maintaining a clear focus on clinical excellence will be paramount in achieving sustained success. Stakeholders must therefore harness emerging insights, collaborative frameworks, and regulatory progress to drive forward innovation and operational efficiency in this ever-evolving field.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of risk factors such as diabetes and hypertension necessitating effective therapies
    • 5.1.1.2. Rising healthcare expenditure encouraging investment in retinal vein occlusion treatment options
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with retinal vein occlusion treatment & limited reimbursement policies
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing advances in gene therapy techniques for long-term management of retinal vein occlusion
    • 5.1.3.2. Adoption of artificial intelligence in early detection and personalized treatment plans for retinal vein occlusion
  • 5.1.4. Challenges
    • 5.1.4.1. Comorbidities complication in patient management for retinal vein occlusion treatment
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type: Wide adoption of anti-VEGF injections to manage macular edema
  • 5.2.2. Condition Type: Growing prevalence of branch retinal vein occlusion boosting demand for advanced treatments
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Retinal Vein Occlusion Treatment Market, by Treatment Type

• 6.1. Introduction
• 6.2. Anti-VEGF Injection
  • 6.2.1. Aflibercept
  • 6.2.2. Bevacizumab
  • 6.2.3. Ranibizumab
• 6.3. Corticosteroid Treatment
• 6.4. Laser Therapy

7. Retinal Vein Occlusion Treatment Market, by Age Group

• 7.1. Introduction
• 7.2. 40-60
• 7.3. Above 60
• 7.4. Below 40

8. Retinal Vein Occlusion Treatment Market, by Condition Type

• 8.1. Introduction
• 8.2. Branch Retinal Vein Occlusion
• 8.3. Central Retinal Vein Occlusion

9. Retinal Vein Occlusion Treatment Market, by End User

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers (ASCs)
• 9.3. Hospitals
• 9.4. Specialty Clinics

10. Americas Retinal Vein Occlusion Treatment Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Retinal Vein Occlusion Treatment Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Retinal Vein Occlusion Treatment Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Scenario Analysis
  • 13.3.1. European Commission approves groundbreaking Vabysmo treatment, revolutionizing retinal vein occlusion care across the EU
  • 13.3.2. Health Canada approves Vabysmo for retinal vein occlusion
  • 13.3.3. Chugai's Vabysmo secures approval as the first bispecific antibody for retinal vein occlusion treatment in Japan
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie
• 2. Alimera Sciences, Inc.
• 3. Bayer AG
• 4. Bristol-Myers Squibb Company
• 5. Carl Zeiss AG
• 6. Fovea Pharmaceuticals SA
• 7. Genentech, Inc.
• 8. GlaxoSmithKline plc
• 9. IRIDEX Corporation
• 10. Johnson & Johnson Services, Inc.
• 11. Lumenis Ltd.
• 12. Novartis AG
• 13. Pfizer Inc.
• 14. Ranbaxy Pharmaceuticals Inc.
• 15. Regeneron Pharmaceuticals, Inc.
• 16. Sanofi S.A.
• 17. Suzuken Co., Ltd.
• 18. Teva Pharmaceutical Industries Ltd.